Eevia Health Plc has secured a bridge loan of SEK 7.5 million

Eevia Health Plc ("Eevia" or "The Company") has entered into an agreement whereby Formue Nord Markedsneutral A/S will provide a bridge loan for Eevia of SEK 7.5 million (EUR 645,000).

Eevia has entered into an agreement whereby Formue Nord Markedsneutral A/S will provide a bridge loan for Eevia of SEK 7.5 million (EUR 645,000). The term of the Bridge loan is until July 31, 2024, and the loan is unsecured. Interest is charged at one (1.0) percent per month and a five (5) percent arrangement fee. Eevia will use approximately SEK 3 million of the loan to repay a credit line from Råsunda Förvaltning AB, Upgrade Invest Nordic AB, and Renewable Ventures Nordic AB. The remainder of the bridge loan will provide for short-term working capital.

This disclosure contains information that EEVIA HEALTH PLC is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication through the contact person's agency on May 20, 2024, at 13:45 CET.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: [email protected]                      

Telephone: +358 400 22 5967        


Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested sustainably.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA.

To learn more, please visit or follow Eevia Health on LinkedIn@EeviaHealth. 

Om Eevia Health

Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.



Kurs ()
Förändring ()
Marknad Spotlight stock market Kortnamn EEVIA ISIN-kod FI4000496658


Stein Ulve IR-kontakt [email protected]